Henderson Global Investors is a global investment company.
Business Model:
Revenue: $907.9M
Employees: 1,001-5,000
Henderson Global Investors was acquired by
Janus Capital Group.
The acquisition happend on 2016-10-03.
Details of the transaction were not public
Address: 201 Bishopsgate
City: London
State: england
Zip: EC2M 3AE
Country: GB
Henderson Group is the holding company of the investment management group Henderson Global Investors. Henderson Group&s;s principal place of business is in London and since December 2003 has been listed on the London Stock Exchange and Australian Securities Exchange - appearing in the FTSE 250 and ASX 100 indices. Henderson Group has approximately 40,000 shareholders worldwide. Since 31 October 2008, the Group has been incorporated in Jersey. Established in 1934 to administer the estates of Alexander Henderson, the first Lord Faringdon, Henderson Global Investors (Henderson) is a leading independent global asset management firm. The company provides its institutional, retail and high net-worth clients access to skilled investment professionals representing a broad range of asset classes, including equities, fixed income, property and alternative investments. With its principal place of business in London, Henderson is one of Europe&s;s largest investment managers, with £92.7bn assets under management and employs around 1000 people worldwide (as at 31 March 2016). In Europe, Henderson has offices in Amsterdam, Edinburgh, Frankfurt, Luxembourg, Madrid, Milan, Paris, Zurich and London. Henderson has had a presence in North America since 1999, when it acquired US real estate investment manager Phoenix Realty Advisers, and has offices in Boston, Chicago and Philadelphia. In Asia, Henderson has offices in New Delhi, Singapore (Asia headquarters), Hong Kong, Tokyo and Beijing as well as in Sydney, Australia. With investment expertise across every asset class, Henderson&s;s skilful investment managers invest in every major market around the globe. They are supported by a global team of researchers and economists who have a keen understanding of the economic forces driving the security markets and who undertake rigorous sector and theme analysis. Underpinning this process is a comprehensive risk-control framework to ensure that investment views are translated into portfolios managed in line with investors&s; risk and return requirements.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2017 | Simba Sleep | Debt Financing | 0 |
4/2008 | Sharda Cropchem | Private Equity Round | 0 |
12/2017 | Simba Sleep | Series B | 0 |
5/2006 | Alaunos Therapeutics | Post-IPO Equity | 0 |
2/2012 | Verona Pharma | Post-IPO Equity | 11.5M |
2/2007 | Alaunos Therapeutics | Post-IPO Equity | 0 |
12/2017 | Simba Sleep | Series B | 0 |
2/2017 | Simba Sleep | Debt Financing | 0 |
2/2012 | Verona Pharma | Post-IPO Equity | 0 |
4/2008 | Sharda Cropchem | Private Equity Round | 0 |
2/2007 | Ziopharm oncology | Post-IPO Equity | 0 |
5/2006 | Ziopharm oncology | Post-IPO Equity | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|